Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.78 |
| ▸ | BCL2L1 | Q07817 | 13/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31011889 | 1.00 | BCL2 (0.78) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL29329427 | 0.99 | BCL2 (0.77) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL31011978 | 0.99 | BCL2 (0.77) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL31011888 | 0.98 | BCL2 (0.77) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL29329371 | 0.98 | BCL2 (0.77) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL31011976 | 0.97 | BCL2 (0.76) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL29329437 | 0.97 | BCL2 (0.76) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL31011823 | 0.97 | BCL2 (0.79) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL29329395 | 0.97 | BCL2 (0.79) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL31011890 | 0.96 | BCL2 (0.77) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885BCL2L1 3/4885CYP3A4 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.